A review on anticancer potential of bioactive heterocycle quinoline

European Journal of Medicinal Chemistry

Volumn 97, Issue 1, 2015, Pages 871-910

  Afzal, Obaid ^a   Kumar, Suresh ^a   Haider, Md Rafi ^a   Ali, Md Rahmat ^a   Kumar, Rajiv ^a   Jaggi, Manu ^b   Bawa, Sandhya ^a  

^a HAMDARD UNIVERSITY   (India)

^b DABUR RESEARCH FOUNDATION   (India)

Author keywords

Anticancer; Drug development; Quinoline

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GUANINE QUADRUPLEX; INTERCALATING AGENT; QUINOLINE DERIVATIVE; QUINOLINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL MIGRATION; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG DNA BINDING; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; LEUKEMIA CELL; METABOLIC STABILITY; MICROTUBULE ASSEMBLY; NON SMALL CELL LUNG CANCER; NONHUMAN; REVIEW; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; QUINOLINES;

EID: 84937217164     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.07.044     Document Type: Review

References (275)

1. S. Kumar, S. Bawa, H. Gupta, Biological activities of quinoline derivatives, Mini Rev. Med. Chem. 9 (2009) 1648-1654.
2. S. Bawa, S. Kumar, S. Drabu, R. Kumar, Structural modifications of quinoline based antimalarial agents: recent developments, J. Pharm. Bioallied Sci. 2 (2010) 64-71.
3. M.E. Wall, M.C. Wani, C.E. Cook, K.H. Palmer, A.I. McPhail, G.A. Sim, Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate, J. Am. Chem. Soc. 88 (1966) 3888-3890.
4. H. Ulukan, P.W. Swaan, Camptothecins, a review of their chemotherapeutical potential, Drugs 62 (2002) 2039-2057.
5. M.R. Redinbo, L. Stewart, P. Kuhn, J.J. Champoux, W.G.J. Hol, Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA, Science 279 (1998) 1504-1513.
6. F. Zunino, S. Dallavalle, D. Laccabue, G. Beretta, L. Merlini, G. Pratesi, Current status and perspectives in the development of camptothecins, Curr. Pharm. Des. 8 (2002) 2505-2520.
7. H. Terasawa, A. Ejima, S. Ohsuki, K. Uoto, Hexa-cyclic compound, U.S. Patent 5, 834, 476 (1998).
8. V. Srivastava, A.S. Negi, J.K. Kumar, M.M. Gupta, S.P.S. Khanuja, Plant-based anticancer molecules: a chemical and biological profile of some important leads, Bioorg. Med. Chem. 13 (2005) 5892-5908.
9. Q. Huang, L. Wang, W. Lu, Evolution in medicinal chemistry of e-ringmodified camptothecin analogs as anticancer agents, Eur. J. Med. Chem. 63 (2013) 746-757.
10. Z. Cao, N. Harris, A. Kozielski, D. Vardeman, J.S. Stehlin, B. Giovanella, Alkyl esters of camptothecin and 9-Nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity, J. Med. Chem. 41 (1998) 31-37.
11. T. Utsugi, K. Aoyagi, T. Asao, S. Okazaki, Y. Aoyagi, M. Sano, K. Wierzba, Y. Yamada, Antitumor activity of a quinoline derivative, TAS-103, with inhibitory effects on topoisomerase I and II, Jpn. J. Cancer Res. 88 (1997) 992-1002.
12. S. Fujimoto, Promising antitumor activity of a novel quinoline derivative, TAS-103, against fresh clinical specimens of eight types of tumors measured by flow cytometric DNA analysis, Biol. Pharm. Bull. 30 (2007) 1923-1929.
13. L.W. Deady, A.J. Kaye, G.J. Finlay, B.C. Baguley, W.A. Denny, Synthesis and antitumor properties of N [2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors, J. Med. Chem. 40, 1997, 2040-2046.
14. L.W. Deady, J.A. Desneves, A.J. Kaye, M. Thompson, G.J. Finlay, B.C. Baguley, W.A. Denny, Ring-substituted 11-oxo-11H-indeno[1, 2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA, Bioorg. Med. Chem. 7 (1999) 2801-2809.
15. M.G. Ferlin, B. Gatto, G. Chiarelotto, M. Palumbo, Novel pyrrolo [3, 2-f]quinolines: synthesis and antiproliferative activity, Bioorg. Med. Chem. 9 (2001) 1843-1848.
16. D.K. Kim, D.H. Ryu, J.Y. Lee, N. Lee, Y.W. Kim, J.S. Kim, K. Chang, G.J. Im, T.K. Kim, W.S. Choi, Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogs, J. Med. Chem. 44 (2001) 1594-1602.
17. A. Perzyna, C. Marty, M. Facompre, J.F. Goossens, N. Pommery, P. Colson, C. Houssier, R. Houssin, J.P. Henichart, C. Bailly, Formaldehyde-induced DNA cross-link of indolizino [1, 2-b]quinolines derived from the A-D rings of camptothecin, J. Med. Chem. 45 (2002) 5809-5812.
18. P. Hautefaye, B. Cimetiere, A. Pierre, S. Leonce, J. Hickman, W. Laine, C. Bailly, G. Laviellea, Synthesis and pharmacological evaluation of novel non-lactone analogs of camptothecin, Bioorg. Med. Chem. Lett. 13 (2003) 2731-2735.
19. X. Xiao, S. Antony, Y. Pommier, M. Cushman, Total synthesis and biological evaluation of 22-hydroxyacuminatine, J. Med. Chem. 49 (2006) 1408-1412.
20. H.K. Rhee, H.J. Park, S.K. Lee, C.O. Lee, H.Y.P. Choo, Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones, Bioorg. Med. Chem. 15 (2007) 1651-1658.
21. L.D. Via, O. Gia, V. Gasparotto, M.G. Ferlin, Discovery of a new anilino-3Hpyrrolo[3, 2-f]quinoline derivative as potential anti-cancer agent, Eur. J. Med. Chem. 43 (2008) 429-434.
22. A. Beauchard, A. Jaunet, L. Murillo, B. Baldeyrou, A. Lansiaux, J.R. Cherouvrier, L. Domon, L. Picot, C. Bailly, T. Besson, V. Thier, Synthesis and antitumoral activity of novel thiazolobenzotriazole, thiazoloindolo [3, 2-c]quinoline and quinolinoquinoline derivatives, Eur. J. Med. Chem. 44 (2009) 3858-3865.
23. Q.D. You, Z.Y. Li, C.H. Huang, Q. Yang, X.J. Wang, Q.L. Guo, X.G. Chen, X.G. He, T.K. Li, J.W. Chern, Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification, J. Med. Chem. 52 (2009) 5649-5661.
24. M.A.L. Mejiá, S.O. V-azquez, K.M. Hern-andez, T.G. Salgado, I.G. S-anchez, F.R. Hern-andez, J.D. Solano, R.R. Sotres, A.L. Rocha, Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structureeactivity relationship of 9-anilinothiazolo[5, 4-b]quinoline derivatives, Bioorg. Med. Chem. 17 (2009) 3266-3277.
25. C.H. Tseng, Y.L. Chen, K.Y. Chung, C.M. Cheng, C.H. Wang, C.C. Tzeng, Synthesis and antiproliferative evaluation of 6-arylindeno [1, 2-c]quinoline derivatives, Bioorg. Med. Chem. 17 (2009) 7465-7476.
26. C.M. Lu, Y.L. Chen, H.L. Chen, C.A. Chen, P.J. Lu, C.N. Yang, C.C. Tzeng, Synthesis and antiproliferative evaluation of certain indolo [3, 2-c]quinoline derivatives, Bioorg. Med. Chem. 18 (2010) 1948-1957.
27. C.H. Tseng, C.C. Tzeng, C.L. Yang, P.J. Lu, H.L. Chen, H.Y. Li, Y.C. Chuang, C.N. Yang, Y.L. Chen, Synthesis and antiproliferative evaluation of certain indeno [1, 2-c]quinoline derivatives, J. Med. Chem. 53 (2010) 6164-6179.
28. I.G. Sanchez, J.D. Solano, M.A.L. Mejiá, S.O. Vazquez, R.R. Sotres, J. Moran, A.L. Rocha, M.A. Cerb-on, Antineoplastic activity of the thiazolo [5, 4-b]quinoline derivative D3CLP in K-562 cells is mediated through effector caspases activation, Eur. J. Med. Chem. 46 (2011) 2102-2108.
29. Y.W. Chen, Y.L. Chen, C.H. Tseng, C.C. Liang, C.N. Yang, Y.C. Yao, P.J. Lu, C.C. Tzeng, Discovery of 4-anilinofuro [2, 3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers, J. Med. Chem. 54 (2011) 4446-4461.
30. W. Luniewski, J. Wietrzyk, J. Godlewska, M. Switalska, M. Piskozub, W.P. Czoch, L. Kaczmarek, New derivatives of 11-methyl-6-[2 (dimethylamino) ethyl]-6Hindolo [2, 3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors, Bioorg. Med. Chem. Lett. 22 (2012) 6103-6107.
31. P. Thapa, R. Karki, H.Y. Yoo, P.H. Park, E. Lee, K.H. Jeon, Y. Na, W.J. Cho, Y. Kwon, E.S. Lee, 2, 4-Diaryl-5, 6-dihydro-1, 10-phenanthroline and 2, 4-diaryl-5, 6-dihydrothieno [2, 3-h] quinoline derivatives for topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study, Bioorg. Chem. 40 (2012) 67-78.
32. S. Chakrabarty, M.S. Croft, M.G. Marko, G. Moyna, Synthesis and evaluation as potential anticancer agents of novel tetracyclic indenoquinoline derivatives, Bioorg. Med. Chem. 21 (2013) 1143-1149.
33. H. Paritala, S.M. Firestine, Benzo(h)quinoline derivatives as G-quadruplex binding agents, Bioorg. Med. Chem. Lett. 19 (2009) 1584-1587.
34. J. Lavrado, A.P. Reszka, R. Moreira, S. Neidle, A. Paulo, C-11 diamino cryptolepine derivatives NSC748392, NSC748393 and NSC748394: anticancer profile and G-quadruplex stabilization, Bioorg. Med. Chem. Lett. 20 (2010) 7042-7045.
35. Y. Xia, Z.Y. Yang, P. Xia, T. Hackl, E. Hamel, A. Mauger, J.H. Wu, K.H. Lee, Fluorinated 2-Phenyl-4-quinolone derivatives as antimitotic antitumor agents, J. Med. Chem. 44 (2001) 3932-3936.
36. Y.L. Chen, C.J. Huang, Z.Y. Huang, C.H. Tseng, F.S. Chang, S.H. Yang, S.R. Lin, C.C. Tzeng, Synthesis and antiproliferative evaluation of certain 4-anilino-8-methoxy-2-phenylquinoline and 4-anilino-8-hydroxy-2-phenylquinoline derivatives, Bioorg. Med. Chem. 14 (2006) 3098-3105.
37. S.Y. Li, Y.L. Chen, C. Wang, C.C. Tzeng, Synthesis and antiproliferative evaluation of certain pyrido [3, 2-g]quinoline derivatives, Bioorg. Med. Chem. 14 (2006) 7370-7376.
38. V. Gasparotto, I. Castagliuolo, M.G. Ferlin, 3-Substituted 7-phenyl pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines, J. Med. Chem. 50( (2007) 5509-5513.
39. C.H. Tseng, Y.L. Chen, P.J. Lu, C.N. Yangd, C.C. Tzeng, Synthesis and antiproliferative evaluation of certain indeno[1, 2-c]quinoline derivatives, Bioorg. Med. Chem. 16 (2008) 3153-3162.
40. I.V. Magedov, M. Manpadi, M.A. Ogasawara, A.S. Dhawan, S. Rogelj, S.V. slambrouck, W.F.A. Steelant, N.M. Evdokimov, P.Y. Uglinskii, E.M. Elias, E.J. Knee, P. Tongwa, M.Y. Antipin, A. Kornienko, Structural simplification of bioactive natural products with multicomponent synthesis. 2. Antiproliferative and antitubulin activities of pyrano[3, 2-c]pyridones and pyrano [3, 2-c]quinolones, J. Med. Chem. 51 (2008) 2561-2570.
41. W. Kemnitzer, J. Kuemmerle, S. Jiang, H.Z. Zhang, N. Sirisoma, S. Kasibhatla, C.C. Grundy, B. Tseng, J. Drewe, S.X. Cai, Discovery of 1-benzoyl-3-cyanopyrrolo[1, 2-a] quinolines as a new series of apoptosis inducers using a cell-and caspase-based high-throughput screening assay. Part 1: structureeactivity relationships of the 1-and 3-positions, Bioorg. Med. Chem. Lett. 18 (2008) 6259-6264.
42. W. Kemnitzer, J. Kuemmerle, S. Jiang, N. Sirisoma, S. Kasibhatla, C.C. Grundy, B. Tseng, J. Drewe, S.X. Cai, Discovery of 1-benzoyl-3-cyanopyrrolo[1, 2-a] quinolines as a new series of apoptosis inducers using a cell-and caspasebased high-throughput screening assay. 2: structure-activity relationships of the 4-, 5-, 6-, 7-and 8-positions, Bioorg. Med. Chem. Lett. 19 (2009) 3481-3484.
43. Y.H. Chang, M.H. Hsu, S.H. Wang, L.J. Huang, K. Qian, S.L.M. Natschke, E. Hamel, S.C. Kuo, K.H. Lee, Design and synthesis of 2-(3-benzo [b]thienyl)-6, 7-methylenedioxyquinolin-4-one analogs as potent antitumor agents that inhibit tubulin assembly, J. Med. Chem. 52 (2009) 4883-4891.
44. C.Y. Nien, Y.C. Chen, C.C. Kuo, H.P. Hsieh, C.Y. Chang, J.S. Wu, S.Y. Wu, J.P. Liou, J.Y. Chang, 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors, J. Med. Chem. 53 (2010) 2309-2313.
45. H.Y. Lee, J.Y. Chang, C.Y. Nien, C.C. Kuo, K.H. Shih, C.H. Wu, C.Y. Chang, W.Y. Lai, J.P. Liou, 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2, J. Med. Chem. 54 (2011) 8517-8525.
46. M.J. Lai, J.Y. Chang, H.Y. Lee, C.C. Kuo, M.H. Lin, H.P. Hsieh, C.Y. Chang, J.S. Wu, S.Y. Wu, K.S. Shey, J.P. Liou, Synthesis and biological evaluation of 1-(40-indolyl and 60-quinolinyl) indoles as a new class of potent anticancer agents, Eur. J. Med. Chem. 46 (2011) 3623-3629.
47. N. Perin, L. Uzelac, I. Piantanida, G.K. Zamola, M. Kralj, M. Hranjec, Novel biologically active nitro and amino substituted benzimidazo [1, 2-a] quinolines, Bioorg. Med. Chem. 19 (2011) 6329-6339.
48. C.H. Tseng, C.C. Tzeng, K.Y. Chung, C.L. Kao, C.Y. Hsu, C.M. Cheng, K.S. Huang, Y.L. Che, Synthesis and antiproliferative evaluation of 6-aryl-11-iminoindeno[1, 2-c] quinoline derivatives, Bioorg. Med. Chem. 19 (2011) 7653-7663.
49. C.T. Chen, M.H. Hsu, Y.Y. Cheng, C.Y. Liu, L.C. Chou, L.J. Huang, T.S. Wu, X. Yang, K.H. Lee, S.C. Kuo, Synthesis and in vitro anticancer activity of 6, 7-methylenedioxy (or 5-hydroxy-6-methoxy)-2-(substituted selenophenyl) quinolin-4-one analogs, Eur. J. Med. Chem. 46 (2011) 6046-6056.
50. C.H. Tseng, Y.L. Chen, C.Y. Hsu, T.C. Chen, C.M. Cheng, H.C. Tso, Y.J. Lu, C.C. Tzeng, Synthesis and antiproliferative evaluation of 3-phenylquinolinyl chalcone derivatives against non-small cell lung cancers and breast cancers, Eur. J. Med. Chem. 59 (2013) 274-282.
51. K. Schiemann, D. Finsinger, F. Zenke, C. Amendt, T. Knochel, D. Bruge, H.P. Buchstaller, U. Emde, W. Stahle, S. Anzali, The discovery and optimization of hexahydro-2H-pyrano[3, 2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5, Bioorg. Med. Chem. Lett. 20 (2010) 1491-1495.
52. H.J. Smith, H. Williams, Introduction to the Principles of Drug Design and Action, fourth ed., CRC Press, 2005, p. 448.
53. Y. Mikata, M. Yokoyama, S.I. Ogura, I. Okura, M. Kawasaki, M. Maeda, S. Yano, Effect of side chain location in (2-aminoethyl)-aminomethyl-2-phenylquinolines as antitumor agents, Bioorg. Med. Chem. Lett. 8 (1998) 1243-1248.
54. M.E. Suh, S.Y. Park, C.O. Lee, Synthesis of pyridino [2, 3-f[indole-4, 9-dione 6, 7-disubstituted quinoline-5, 8-dione derivatives and evaluation on their cytotoxic activity, Bioorg. Med. Chem. 9 (2001) 2979-2986.
55. L.T. Bozic, F. Frausin, V. Scarcia, A. Furlani, Synthesis, characterization and antitumor activity of platinum(II) complexes with diethyl and monoethyl 2 quinolylmethyl phosphonates, J. Inorg. Biochem. 95 (2003) 259-269.
56. S.C. Chackal, M. Facompre, R. Houssin, N. Pommery, J.F. Goossens, P. Colson, C. Bailly, J.P. Henichart, DNA binding to guide the development of tetrahydroindeno [1, 2-b]pyrido[4, 3, 2-de]quinoline derivatives as cytotoxic agents, J. Med. Chem. 47 (2004) 3665-3673.
57. P.R. Loaiza, A. Quintero, R.R. Sotres, J.D. Solano, A.L. Rocha, Synthesis and evaluation of 9-anilinothiazolo [5, 4-b]quinoline derivatives as potential antitumorals, Eur. J. Med. Chem. 39 (2004) 5-10.
58. A.A. Bekhit, O.A. El-Sayed, T.A.K. Al-Allaf, H.Y. Aboul-Enein, M. Kunhi, S.M. Pulicat, K. Al-Hussain, F. Al-Khodairy, J. Arif, Synthesis, characterization and cytotoxicity evaluation of some new platinum(II) complexes of tetrazolo [1, 5-a] quinolines, Eur. J. Med. Chem. 39 (2004) 499-505.
59. D. Sharples, C. Spengler, J. Molnar, Z. Antal, A. Molnar, J.T. Kiss, J.A. Szabo, A. Hilgeroth, S. Gallo, A. Mohamoud, J. Barbe, The interaction between resistance modifiers such pyrido[3, 2-g]quinoline, aza-oxafluorene and pregnane derivatives with DNA, plasmid DNA and tRNA, Eur. J. Med. Chem. 40 (2005) 195-202.
60. L. Tusek-Bozic, M. Juribasic, P. Traldi, V. Scarcia, A. Furlani, Synthesis, characterization and antitumor activity of palladium(II) complexes of monoethyl 8-quinolylmethylphosphonate, Polyhedron 27 (2008) 1317-1328.
61. M.S. Shahabuddin, M. Gopal, Sathees C. Raghavan, Intercalating, cytotoxic, antitumour activity of 8-chloro and 4-morpholinopyrimido [40, 50:4, 5] thieno(2, 3-b)quinolines, J. Photochem. Photobiol. B 94 (2009) 13-19.
62. Z.C. Liu, B.D. Wang, Z.Y. Yang, Y. Li, D.D. Qin, T.R. Li, Synthesis, crystal structure, DNA interaction and antioxidant activities of two novel watersoluble Cu(2\+) complexes derivated from 2-oxo-quinoline-3-carbaldehyde Schiff-bases, Eur. J. Med. Chem. 44 (2009) 4477-4484.
63. N. Gligorijevic, T. Todorovic, S. Radulovic, D. Sladic, N. Filipovic, D. GoCevac, D. Jeremic, K. AnCelkovic, Synthesis and characterization of new Pt(II) and Pd(II) complexes with 2-quinolinecarboxaldehyde selenosemicarbazone: cytotoxic activity evaluation of Cd(II), Zn(II), Ni(II), Pt(II) and Pd(II) complexes with heteroaromatic selenosemicarbazones, Eur. J. Med. Chem. 44 (2009) 1623-1629.
64. M. Szumilak, A.S. Mroczek, K. Koprowska, M. Stasiak, W. Lewgowd, A. Stanczak, M. Czyz, Synthesis and in vitro biological evaluation of new polyamine conjugates as potential anticancer drugs, Eur. J. Med. Chem. 45 (2010) 5744-5751.
65. R. Kakadiya, H. Dong, A. Kumar, D. Narsinh, X. Zhang, T.C. Chou, T.C. Lee, A. Shah, T.L. Su, Potent DNA-directed alkylating agents: synthesis and biological activity of phenyl N-mustard-quinoline conjugates having a urea or hydrazinecarboxamide linker, Bioorg. Med. Chem. 18 (2010) 2285-2299.
66. S. Chavda, B. Babu, S.K. Yanow, A. Jardim, T.W. Spithill, K. Kiakos, J. Kluza, J.A. Hartley, M. Lee, A novel achiral seco-cyclopropylpyrido [e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation, Bioorg. Med. Chem. 18 (2010) 5016-5024.
67. F.R. Krause, A. Eick, R. Grünert, P.J. Bednarski, K. Weisz, In vitro anticancer activity and evaluation of DNA duplex binding affinity of phenyl-substituted indoloquinolines, Bioorg. Med. Chem. Lett. 21 (2011) 2380-2383.
68. M. Juribasic, K. Molcanov, B.K. Prodic, L. Bellotto, M. Kralj, F. Zani, L.T. Bozi, Palladium(II) complexes of quinolinylaminophosphonates: synthesis, structural characterization, antitumor and antimicrobial activity, J. Inorg. Biochem. 105 (2011) 867-879.
69. L.K. Filak, S. Goschl, S. Hackl, M.A. Jakupec, V.B. Arion, Ruthenium-and osmium-arene complexes of 8-substituted indolo[3, 2-c]quinolines: synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity, Inorg. Chim. Acta 393 (2012) 252-260.
70. A.E. Ruiz, C. Herrmann, J. Chen, B.O. Patrick, E. Polishchuk, C. Orvig, Synthesis and in vitro anticancer activity of ferrocenyl-aminoquinoline-carboxamide conjugates, Inorg. Chim. Acta 393 (2012) 276-283.
71. E. Ramachandran, S.P. Thomas, P. Poornima, P. Kalaivani, R. Prabhakaran, V.V. Padma, K. Natarajan, Evaluation of DNA binding, antioxidant and cytotoxic activity of mononuclear Co(III) complexes of 2-oxo-1, 2-dihydrobenzo [h]quinoline-3-carbaldehyde thiosemicarbazones, Eur. J. Med. Chem. 50 (2012) 405-415.
72. P.J. Bindu, K.M. Mahadevan, T.R.R. Naik, An efficient one-pot synthesis and photoinduced DNA cleavage studies of 2-chloro-3-(5-aryl-4, 5-dihydroisoxazol-3-yl)quinolines, Bioorg. Med. Chem. Lett. 22 (2012) 6095-6098.
73. C.H. Tseng, Y.L. Chen, C.L. Yang, C.M. Cheng, C.H. Han, C.C. Tzeng, Synthesis of 6-substituted 9-methoxy-11H-indeno[1, 2-c]quinoline-11-one derivatives as potential anticancer agents, Bioorg. Med. Chem. 20 (2012) 4397-4404.
74. H.M. Faidallah, S.A.F. Rostomb, Synthesis, in vitro antitumor evaluation and DNA-binding study of novel tetrahydroquinolines and some derived tricyclic and tetracyclic ring systems, Eur. J. Med. Chem. 63 (2013) 133-143.
75. M.B. El-Ashmawy, M.A. El-Sherbeny, N.S. El-Gohary, Synthesis and antitumor screening of new series of pyrimido-[4, 5-b]quinolines and [1, 2, 4]triazolo[20, 30:3, 4] pyrimido[6, 5-b]quinolines, Med. Chem. Res., http://dx.doi.org/10. 1007/s00044-012-0272-y.
76. N. Perin, R. Nhili, K. Ester, W. Laine, G. Karminski-Zamola, M. Kralj, M.H. David-Cordonnier, M. Hranje, Synthesis, antiproliferative activity and DNA binding properties of novel 5-aminobenzimidazo[1, 2-a] quinoline-6-carbonitriles, Eur. J. Med. Chem. 80 (2014) 218-227.
77. D.L. Dexter, D.P. Hesson, R.J. Ardecky, G.V. Rao, D.L. Tiffett, B.A. Dusak, K.D. Paull, J. Plowman, B.M. Delarco, V.L. Narayanan, M. Forbes, Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(20-fluoro-1, 10-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt], against experimental tumors, Cancer Res. 45 (1985) 5563-5568.
78. S.F. Chen, R.L. Ruben, D.L. Dexter, Mechanism of action of the novel anticancer agent 6-fluoro-2-(20-fluoro-1, 10-biphenyl-4-YL)-3-methyl-4-quinolinecarboxylic acid sodium salt (NSC368390): inhibition of de novo pyrimidine nucleotide biosynthesis, Cancer Res. 46 (1986) 5014-5019.
79. G.J. Peters, S.L. Sharma, E. Laurensse, H.M. Pinedo, Inhibition of pyrimidine de novo synthesis by DUP 785 (NSC 368390), Investig. New Drugs 5 (1987) 235-244.
80. P. Warner, A.J. Barker, A.L. Jackman, K.D. Burrows, N. Roberts, J.A. Bishop, B.M. O0Connor, L.R. Hughes, Quinoline antifolate thymidylate synthase inhibitors: variation of the C2-and C4-substituents, J. Med. Chem. 35 (1992) 2761-2768.
81. M. Whitnall, J. Howard, P. Ponka, D.R. Richardson, A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 14901-14906.
82. M. Serda, D.S. Kalinowski, A.M. Wilczkiewicz, R. Musiol, A. Szurko, A. Ratuszna, N. Pantarat, Z. Kovacevic, A.M. Merlot, D.R. Richardson, J. Polanski, Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to antitumor efficacy, Bioorg. Med. Chem. Lett. 22 (2012) 5527-5531.
83. F. Saczewski, A. Innocenti, J. Slawinski, A. Kornicka, Z. Brzozowski, E. Pomarnacka, A. Scozzafava, C. Temperini, C.T. Supuran, Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumorassociated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides, Bioorg. Med. Chem. 16 (2008) 3933-3940.
84. W.R. Chegwidden, I.M. Spencer, Sulphonamide inhibitors of carbonic anhydrase inhibit the growth of human lymphoma cells in culture, Inflammopharmacology 3 (1995) 231-239.
85. M.M. Ghorab, F.A. Ragab, M.M. Hamed, Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety, Eur. J. Med. Chem. 44 (2009) 4211-4217.
86. M.S. Al-Said, M.M. Ghorab, S.I. Al-qasoumi, E.M. El-Hossary, E. Noaman, Synthesis and in vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5, 6, 7, 8-tetrahydroquinolin-1-(4H)-yl]benzenesulfonamides, Eur. J. Med. Chem. 45 (2010) 3011-3018.
87. M.M. Ghorab, F.A. Ragab, H.I. Heiba, R.K. Arafa, E.M. El-Hossary, In vitro anticancer screening and radiosensitizing evaluation of some new quinolines and pyrimido[4, 5-b]quinolines bearing a sulfonamide moiety, Eur. J. Med. Chem. 45 (2010) 3677-3684.
88. S.I. Alqasoumi, A.M. Al-Taweel, A.M. Alafeefy, E. Noaman, M.M. Ghorab, Novel quinolines and pyrimido[4, 5-b]quinolines bearing biologically active sulfonamide moiety as a new class of antitumor agents, Eur. J. Med. Chem. 45 (2010) 738-744.
89. M.M. Ghorab, F.A. Ragab, H.I. Heiba, R.K. Arafa, E.M. El-Hossary, Docking study, in vitro anticancer screening and radiosensitizing evaluation of some new fluorine-containing quinoline and pyrimidoquinoline derivatives bearing a sulfonamide moiety, Med. Chem. Res. 20 (2011) 388-400.
90. M.S. Al-Said, M.M. Ghorab, M.S. Al-Dosari, M.M. Hamed, Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety, Eur. J. Med. Chem. 46 (2011) 201-207.
91. D.E. Gomez, R.G. Armando, D.F. Alonso, AZT as a telomerase inhibitor, Front. Oncol. 2 (2012) 113.
92. V. Caprio, B. Guyen, Y.O. Boahen, J. Mann, S.M. Gowan, L.M. Kelland, M.A. Read, S. Needle, A novel inhibitor of human telomerase derived from 10H-indolo[3, 2-b]quinoline, Bioorg. Med. Chem. Lett. 10 (2000) 2063-2066.
93. J.L. Zhou, Y.J. Lu, T.M. Ou, J.M. Zhou, Z.S. Huang, X.F. Zhu, C.J. Du, X.Z. Bu, L. Ma, L.Q. Gu, Y.M. Li, A.S.C. Chan, Synthesis and evaluation of quindoline derivatives as G-quadruplex inducing and stabilizing ligands and potential inhibitors of telomerase, J. Med. Chem. 48 (2005) 7315-7321.
94. J. Sun, H. Zhu, Z.M. Yang, H.L. Zhu, Synthesis, molecular modeling and biological evaluation of 2-aminomethyl-5-(quinolin-2-yl)-1, 3, 4-oxadiazole-2(3H)-thione quinolone derivatives as novel anticancer agent, Eur. J. Med. Chem. 60 (2013) 23-28.
95. L.G. Hamann, R.I. Higuchi, L. Zhi, J.P. Edwards, X.N. Wang, K.B. Marschke, J.W. Kong, L.J. Farmer, T.K. Jones, Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1, 2-dihydropyridono [5, 6-g]quinolines, J. Med. Chem. 41 (1998) 623-639.
96. A. Maiti, P.V.N. Reddy, M. Sturdy, L. Marler, S.D. Pegan, A.D. Mesecar, J.M. Pezzuto, M. Cushman, Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities, J. Med. Chem. 52 (2009) 1873-1884.
97. C.M. Tegley, L. Zhi, K.B. Marschke, M.M. Gottardis, Q. Yang, T.K. Jones, 5-Benzylidene 1, 2-dihydrochromeno[3, 4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists, J. Med. Chem. 41 (1998) 4354-4359.
98. L. Zhi, C.M. Tegley, K.B. Marschke, D.E. Mais, T.K. Jones, 5-Aryl-1, 2, 3, 4-tetrahydrochromeno[3, 4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification, J. Med. Chem. 42 (1999) 1466-1472.
99. L. Zhi, C.M. Tegley, B. Pio, J.P. Edwards, M. Motamedi, T.K. Jones, K.B. Marschke, D.E. Mais, B. Risek, W.T. Schrader, 5-Benzylidene-1, 2-dihydrochromeno[3, 4-f]quinolines as selective progesterone receptor modulators, J. Med. Chem. 46 (2003) 4104-4112.
100. B. Pedram, A.V. Oeveren, D.E. Mais, K.B. Marschke, P.M. Verbost, M.B. Groen, L. Zhi, A tissue-selective nonsteroidal progesterone receptor modulator: 7, 9-difluoro-5-(3-methylcyclohex-2-enyl)-2, 2, 4-trimethyl-1, 2-dihydrochromeno [3, 4-f]quinoline, J. Med. Chem. 51 (2008) 3696-3699.
101. I. Fernandes, N. Vale, V. deFreitas, R. Moreira, N. Mateus, P. Gomes, Antitumoral activity of imidazoquines, a new class of antimalarials derived from primaquine, Bioorg. Med. Chem. Lett. 19 (2009) 6914-6917.
102. A.E. Rashad, W.A. El-Sayed, A.M. Mohamed, M.M. Ali, Synthesis of new quinoline derivatives as inhibitors of human tumor cells growth, Arch. Pharm. 343 (2010) 440-448.
103. H. Jiang, J.E. Taggart, X. Zhang, D.M. Benbrook, S.E. Lind, W.Q. Ding, Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline), Cancer Lett. 312 (2011) 11-17.
104. N. Mulakayala, D. Rambabu, M.R. Raja, M. Chaitanya, C.S. Kumar, A.M. Kalle, G.R. Krishna, C.M. Reddy, M.V.B. Rao, M. Pal, Ultrasound mediated catalyst free synthesis of 6H-1-benzopyrano[4, 3-b]quinolin-6-ones leading to novel quinoline derivatives: their evaluation as potential anti-cancer agents, Bioorg. Med. Chem. 20 (2012) 759-768.
105. P.V.N. Reddy, K.C. Jensen, A.D. Mesecar, P.E. Fanwick, M. Cushman, Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogs as inhibitors of quinone reductase 2, J. Med. Chem. 55 (2012) 367-377.
106. C.R. Calabrese, R. Almassy, S. Barton, M.A. Batey, A.H. Calvert, S.C. Koch, B.W. Durkacz, Z. Hostomsky, R.A. Kumpf, S. Kyle, J. Li, K. Maegley, D.R. Newell, E. Notarianni, I.J. Stratford, D. Skalitzky, H.D. Thomas, L.Z. Wang, S.E. Webber, K.J. Williams, N.J. Curtin, Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361, J. Natl. Cancer Inst. 96 (2004) 56-67.
107. A.M. Lord, M.F. Mahon, M.D. Lloyd, M.D. Threadgill, Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor, J. Med. Chem. 52 (2009) 868-877.
108. C.H. Park, K. Chun, B.Y. Joe, J.H. Choi, H.C. Lee, I.W. Ku, H.Y. Kim, S.H. Koh, G.W. Cho, S.H. Kim, M.H. Kim, Synthesis and evaluation of thiopyrano[3, 4-c] quinoline-9-carboxamide derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1), Med. Chem. Res. 21 (2012) 1533-1543.
109. H. Peng, D.I. Kim, J.N. Sarkaria, Y.S. Cho, R.T. Abraham, L.H. Zalkow, Novel pyrrolo-quinoline derivatives as potent inhibitors for PI3-kinase related kinases, Bioorg. Med. Chem. 10 (2002) 167-174.
110. Q. Liu, J.W. Chang, J. Wang, S.A. Kang, C.C. Thoreen, A. Markhard, W. Hur, J. Zhang, T. Sim, D.M. Sabatini, N.S. Gray, Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl) benzo[h] [1, 6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer, J. Med. Chem. 53 (2010) 7146-7155.
111. Q. Liu, J. Wang, S.A. Kang, C.C. Thoreen, W. Hur, T. Ahmed, D.M. Sabatini, N.S. Gray, Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl) phenyl)benzo [h] [1, 6] naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer, J. Med. Chem. 54 (2011) 1473-1480.
112. S. Boldt, W. Kolch, Targeting MAPK signalling: prometheus' fire or pandora's box Curr. Pharm. Des. 10 (2004) 1885-1905.
113. C. Peifer, K. Kinkel, M. Abadleh, D. Schollmeyer, S. Laufer, From five-to sixmembered rings: 3, 4-diarylquinolinone as lead for novel p38MAP kinase inhibitors, J. Med. Chem. 50 (2007) 1213-1221.
114. D.M. Berger, M. Dutia, D. Powell, M.B. Floyd, N. Torres, R. Mallon, D. Wojciechowicz, S. Kim, L. Feldberg, K. Collins, I. Chaudhary, 4-Anilino-7-alkenyl quinoline-3-carbonitriles as potent MEK1 kinase inhibitors, Bioorg. Med. Chem. 16 (2008) 9202-9211.
115. D.W. Litchfield, Protein kinase CK2: structure, regulation and role in cellular decisions of life and death, Biochem. J. 369 (2003) 1-15.
116. B. Guerra, O.G. Issinger, Protein kinase CK2 in human diseases, Curr. Med. Chem. 15 (2008) 1870-1886.
117. E.L. Bollag, R.R. Mourez, D.H. Song, G.E. Sonenshein, R.D. Cardiff, D.C. Seldin, Protein kinase CK2 in mammary gland tumorigenesis, Oncogene 20 (2001) 3247-3257.
118. P.O. Charoenrat, V. Rusch, S.G. Talbot, Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung, Clin. Cancer Res. 10 (2004) 5792-5803.
119. M. Laramas, D. Pasquier, O. Filhol, F. Ringeisen, J.L. Descotes, Nuclear localization of protein kinase CK2 catalytic subunit (CK2a) is associated with poor prognostic factors in human prostate cancer, Eur. J. Cancer 43 (2007) 928-934.
120. K. Pistorius, G. Seitz, K. Remberger, O.G. Issinger, Differential CKII activities in human colorectal mucosa, adenomas and carcinomas, Onkologie 14 (1991) 256-260.
121. G. Stalter, S. Siemer, E. Becht, M. Ziegler, K. Remberger, O.G. Issinger, Asymmetric expression of protein kinase CK2 subunits in human kidney tumors, Biochem. Biophys. Res. Commun. 202 (1994) 141-147.
122. J.S. Kim, J.I. Eom, J.W. Cheong, Protein kinase CK2a as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia, Clin. Cancer Res. 13 (2007) 1019-1028.
123. P. Jasinski, B. Welsh, J. Galvez, D. Land, P. Zwolak, L. Ghandi, K. Terai, A.Z. Dudek, A novel quinoline, MT477: suppresses cell signalling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo antitumor activity against human carcinoma cell lines, Investig. New Drugs 26 (2008) 223-232.
124. P. Jasinski, P. Zwolak, K. Terai, D.B. Cacho, A.Z. Dudek, PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis, Investig. New Drugs 29 (2011) 33-40.
125. A.S. Jain, D. Drygin, N. Streiner, P. Chua, F. Pierre, S.E. O'Brien, J. Bliesath, M. Omori, N. Huser, C. Ho, C. Proffitt, M.K. Schwaebe, D.M. Ryckman, W.G. Rice, K. Anderes, CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy, Cancer Res. 70 (2010) 10288-10298.
126. F. Pierre, P.C. Chua, S.E. O'Brien, A.S. Jain, P. Bourbon, M. Haddach, J. Michaux, J. Nagasawa, M.K. Schwaebe, E. Stefan, A. Vialettes, J.P. Whitten, T.K. Chen, L. Darjania, R. Stansfield, K. Anderes, J. Bliesath, D. Drygin, C. Ho, M. Omori, C. Proffitt, N. Streiner, K. Trent, W.G. Rice, D.M. Ryckman, Discovery and SAR of 5-(3-chlorophenylamino) benzo [c] [2, 6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer, J. Med. Chem. 54 (2011) 635-654.
127. M. Haddach, F. Pierre, C.F. Regan, C. Borsan, J. Michaux, E. Stefan, P. Kerdoncuff, M.K. Schwaebe, P.C. Chua, A.S. Jain, D. Macalino, D. Drygin, S.E. O'Brien, W.G. Rice, D.M. Ryckman, Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs, Bioorg. Med. Chem. Lett. 22 (2012) 45-48.
128. Y. Mettey, J.M. Vierfond, Benzo [c]quinoliziniums: a new family of inhibitors for protein kinase CK II, Bioorg. Med. Chem. Lett. 7 (1997) 961-964.
129. A.G. Golub, O.Y. Yakovenko, V.G. Bdzhola, V.M. Sapelkin, P. Zien, S.M. Yarmoluk, Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2, J. Med. Chem. 49 (2006) 6443-6450.
130. M.A.L. Meji, K.M. Hernandez, F.R. Hernandez, R.R. Sotres, I.G. Sanchez, A. Quintero, J.D. Solanoc, A.L. Rochaa, Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5, 4-b]quinoline derivatives, Bioorg. Med. Chem. 16 (2008) 1142-1149.
131. S. Mollin, S. Blanck, K. Harms, E. Meggers, Cyclometalated phenylquinoline rhodium complexes as protein kinase inhibitors, Inorg. Chim. Acta 393 (2012) 261-268.
132. R.H. Gunby, S. Ahmed, R. Sottocornola, M. Gasser, S. Redaelli, L. Mologni, C.J. Tartari, V. Belloni, C.G. Passerini, L. Scapozza, Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor, binding analysis, and homology modeling, J. Med. Chem. 49 (2006) 5759-5768.
133. M. Puttini, A.M. Coluccia, F. Boschelli, L. Cleris, E. Marchesi, A.D. Deana, S. Ahmed, S. Redaelli, R. Piazza, V. Magistroni, F. Andreoni, L. Scapozza, F. Formelli, C.G. Passerini, In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl\+ neoplastic cells, Cancer Res. 23 (2006) 11314-11322.
134. A. Vultur, R. Buettner, C. Kowolik, SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells, Mol. Cancer Ther. 7 (2008) 1185-1194.
135. J.E. Cortes, H.M. Kantarjian, T.H. Brümmendorf, D.W. Kim, A.G. Turkina, Z.X. Shen, R. Pasquini, H.J. Khoury, S. Arkin, A. Volkert, N. Besson, R. Abbas, J. Wang, E. Leip, C.G. Passerini, Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib, Blood 17 (2011) 4567-4576.
136. J.E. Cortes, D.W. Kim, H.M. Kantarjian, T.H. Brümmendorf, I. Dyagil, L. Griskevicus, H. Malhotra, C. Powell, K. Gogat, A.M. Countouriotis, C.G. Passerini, Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial, J. Clin. Oncol. 30 (2012) 3486-3492.
137. R. Abbas, B.A. Hug, C. Leister, M.E. Gaaloul, S. Chalon, D. Sonnichsen, A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects, Cancer Chemother. Pharmacol. 69 (2012) 221-227.
138. R. Abbas, S. Chalon, C. Leister, M.E. Gaaloul, D. Sonnichsen, Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects, Cancer Chemother. Pharmacol. 71 (2013) 123-132.
139. D.H. Boschelli, Y.D. Wang, F. Ye, B. Wu, N. Zhang, M. Dutia, D.W. Powell, A. Wissner, K. Arndt, J.M. Weber, F. Boschelli, Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles, J. Med. Chem. 44 (2001) 822-833.
140. D.M. Berger, M. Dutia, G. Birnberg, D. Powell, D.H. Boschelli, Y.D. Wang, M. Ravi, D. Yaczko, J. Golas, J. Lucas, F. Boschelli, 4-Anilino-7, 8-dialkoxybenzo [g]quinoline-3-carbonitriles as potent Src kinase inhibitors, J. Med. Chem. 48 (2005) 5909-5920.
141. X. Cao, Q.D. You, Z.Y. Li, Q.L. Guo, J. Shang, M. Yan, J.W. Chern, M.L. Chen, Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase, Bioorg. Med. Chem. 16 (2008) 5890-5898.
142. Y.D. Wang, K. Miller, D.H. Boschelli, F. Ye, B. Wu, M.B. Floyd, D.W. Powell, A. Wissner, J.M. Weber, F. Boschelli, Inhibitors of Src tyrosine kinase: the preparation and structureeactivity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines, Bioorg. Med. Chem. Lett. 10 (2000) 2477-2480.
143. J.P. Golden, J.A. DeMaro, P.A. Osborne, J. Milbrandt, E.M. Johnson Jr., Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse, Exp. Neurol. 158 (1999) 504-528.
144. E. Arighi, M.G. Borrello, H. Sariola, RET tyrosine kinase signaling in development and cancer, Cytokine Growth Factor Rev. 16 (2005) 441-467.
145. M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P.B. Peccoz, C. Bordi, B.C. Devolx, A. Falchetti, R.G. Gheri, A. Libroia, C.J. Lips, G. Lombardi, M. Mannelli, F. Pacini, B.A. Ponder, F. Raue, B. Skogseid, G. Tamburrano, R.V. Thakker, N.W. Thompson, P. Tomassetti, F. Tonelli, S.A.J. Wells, S.J.J. Marx, CONSENSUS: guidelines for diagnosis and therapy of MEN type 1 and type 2, J. Clin. Endocrinol. Metab. 86 (2001) 5658-5671.
146. R.G. Robinett, A.J. Freemerman, M.A. Skinner, L. Shewchuka, K. Lackeya, The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors, Bioorg. Med. Chem. Lett. 17 (2007) 5886-5893.
147. C. Birchmeier, W. Birchmeier, E. Gherardi, G.F. Vande Woude, Met, metastasis, motility and more, Nat. Rev. Mol. Cell Biol. 4 (2003) 915-925.
148. M. Okigaki, M. Komada, Y. Uehara, K. Miyazawa, N. Kitamura, Functional characterization of human hepatocyte growth factor mutants obtained by deletion of structural domains, Biochemistry 31 (1992) 9555-9561.
149. S. Bellusci, G. Moens, G. Gaudino, P. Comoglio, T. Nakamura, J.P. Thiery, J. Jouanneau, Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity, Oncogene 9 (1994) 1091-1099.
150. Y. Wang, J. Ai, Y. Wang, Y. Chen, L. Wang, G. Liu, M. Geng, A. Zhang, Synthesis and c-met kinase inhibition of 3, 5-disubstituted and 3, 5, 7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7-(trifluoromethyl) quinoline as a novel anticancer agent, J. Med. Chem. 54 (2011) 2127-2142.
151. J.J. Cui, M. McTigue, M. Nambu, M.T. Dube, M. Pairish, H. Shen, L. Jia, H. Cheng, J. Hoffman, P. Le, M. Jalaie, G.H. Goetz, K. Ryan, N. Grodsky, Y. Deng, M. Parker, S. Timofeevski, B.W. Murray, S. Yamazaki, S. Aguirre, Q. Li, H. Zou, J. Christensen, Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1, 2, 3]triazolo[4, 5-b]pyrazin-6-yl)-1H-pyrazol-1-yl) ethanol (PF-04217903) for the treatment of cancer, J. Med. Chem. 55 (2012) 8091-8109.
152. M. Prewett, J. Huber, Y. Li, A. Santiago, W. O'Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, P. Bohlen, D.J. Hicklin, Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors, Cancer Res. 59 (1999) 5209-5218.
153. M.M. Weiss, J.C. Harmange, A.J. Polverino, D. Bauer, L. Berry, V. Berry, G. Borg, J. Bready, D. Chen, D. Choquette, A. Coxon, T. DeMelfi, N. Doerr, J. Estrada, J. Flynn, R.F. Graceffa, S.P. Harriman, S. Kaufman, D.S. La, A. Long, S. Neervannan, V.F. Patel, M. Potashman, K. Regal, P.M. Roveto, M.L. Schrag, C. Starnes, A. Tasker, Y. Teffera, D.A. Whittington, R. Zanon, Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors, J. Med. Chem. 51 (2008) 1668-1680.
154. Y. Yang, L. Shi, Y. Zhou, H.Q. Li, Z.W. Zhu, H.L. Zhu, Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors, Bioorg. Med. Chem. Lett. 20 (2010) 6653-6656.
155. K. Kubo, T. Shimizu, S. Ohyama, H. Murooka, A. Iwai, K. Nakamura, K. Hasegawa, Y. Kobayashi, N. Takahashi, K. Takahashi, S. Kato, T. Izawa, T. Isoe, Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N0-{4-(4-quinolyloxy)phenyl}ureas, J. Med. Chem. 48 (2005) 1359-1366.
156. J. Ren, J. Zhao, Y.S. Zhou, X.H. Liu, X. Chen, K. Hu, Synthesis and antitumor activity of novel 4-aminoquinoline derivatives, Med. Chem. Res. 22 (2013) 2855-2861.
157. K.S. Kolibaba, B.J. Druker, Protein tyrosine kinases and cancer, Biochim. Biophys. Acta 1333 (1997) 217-248.
158. M. Tateishi, T. Ishida, T. Mitsudomi, S. Kaneko, K. Sugimachi, Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung, Cancer Res. 50 (1990) 7077-7080.
159. T.P. Fleming, A. Saxena, W.C. Clark, J.T. Robertson, E.H. Oldfield, S.A. Aaronson, I.U. Ali, Amplification and/or overexpression of plateletderived growth factor receptors and epidermal growth factor receptor in human glial tumors, Cancer Res. 52 (1992) 4550-4553.
160. D.M. Shin, J.Y. Ro, W.K. Hong, W.N. Hittelamn, Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis, Cancer Res. 54 (1994) 3153-3159.
161. V.G. Pawar, M.L. Sos, H.B. Rode, M. Rabiller, S. Heynck, W.A.L. VanOtterlo, R.K. Thomas, D. Rauh, Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor, J. Med. Chem. 53 (2010) 2892-2901.
162. S. Li, C. Guo, X. Sun, Y. Li, H. Zhao, D. Zhan, M. Lan, Y. Tang, Synthesis and biological evaluation of quinazoline and quinoline bearing 2, 2, 6, 6 tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor( EGFR) tyrosine kinase inhibitors and EPR bio-probe agents, Eur. J. Med. Chem. 49 (2012) 271-278.
163. A. Wissner, D.M. Berger, D.H. Boschelli, M.B. Floyd Jr., L.M. Greenberger, B.C. Gruber, B.D. Johnson, N. Mamuya, R. Nilakantan, M.F. Reich, R. Shen, H.R. Tsou, E. Upeslacis, Y.F. Wang, B. Wu, F. Ye, N. Zhang, 4-Anilino-6, 7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6, 7-dialkoxyquinazoline inhibitors, J. Med. Chem. 43 (2000) 3244-3256.
164. A. Wissner, E. Overbeek, M.F. Reich, M.B. Floyd, B.D. Johnson, N. Mamuya, E.C. Rosfjord, C. Discafani, R. Davis, X. Shi, S.K. Rabindran, B.C. Gruber, F. Ye, W.A. Hallett, R. Nilakantan, R. Shen, Y.F. Wang, L.M. Greenberger, H.R. Tsou, Synthesis and structure-activity relationships of 6, 7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2), J. Med. Chem. 46 (2003) 49-63.
165. H.R. Tsou, E.G.O. Klumpers, W.A. Hallett, M.F. Reich, M.B. Floyd, B.D. Johnson, R.S. Michalak, R. Nilakantan, C. Discafani, J. Golas, S.K. Rabindran, R. Shen, X. Shi, Y.F. Wang, J. Upeslacis, A. Wissner, Optimization of 6, 7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity, J. Med. Chem. 48 (2005) 1107-1131.
166. C.B. Sangani, J.A. Makawana, X. Zhang, S.B. Teraiya, L. Lin, H.L. Zhu, Design, synthesis and molecular modeling of pyrazole-quinoline-pyridine hybrids as a new class of antimicrobial and anticancer agents, Eur. J. Med. Chem. 76 (2014) 549-557.
167. J.A. Makawana, C.B. Sangani, L. Lin, H.L. Zhu, Schiff's base derivatives bearing nitroimidazole and quinoline nuclei: new class of anticancer agents and potential EGFR tyrosine kinase inhibitors, Eur. J. Med. Chem. 24 (2014) 1734-1736.
168. L.M. Miller, S.C. Mayer, D.M. Berger, D.H. Boschelli, F. Boschelli, L. Di, X. Du, M. Dutia, M.B. Floyd, M. Johnson, C.H. Kenny, G. Krishnamurthy, F. Moy, S. Petusky, D. Tkach, N. Torres, B. Wu, W. Xu, Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment, Bioorg. Med. Chem. Lett. 19 (2009) 62-66.
169. L.C. Chou, M.T. Tsai, M.H. Hsu, S.H. Wang, T.D. Way, C.H. Huang, H.Y. Lin, K. Qian, Y. Dong, K.H. Lee, L.J. Huang, S.C. Kuo, Design, synthesis, and preclinical evaluation of new 5, 6-(or 6, 7-) disubstituted-2-(fluorophenyl)quinolin-4-one derivatives as potent antitumor agents, J. Med. Chem. 53 (2010) 8047-8058.
170. D.A. Scott, C.L. Balliet, D.J. Cook, A.M. Davies, T.W. Gero, C.A. Omer, S. Poondru, M.E. Theoclitou, B. Tyurin, M.J. Zinda, Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase, Bioorg. Med. Chem. Lett. 19 (2009) 697-700.
171. D.A. Scott, K.J. Bell, C.T. Campbell, D.J. Cook, L.A. Dakin, D.J.D. Valle, L. Drew, T.W. Gero, M.M. Hattersley, C.A. Omer, B. Tyurin, X. Zheng, 3-Amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: optimization of the PK profile, Bioorg. Med. Chem. Lett. 19 (2009) 701-705.
172. J.M. Yingling, K.L. Blanchard, J.S. Sawyer, Development of TGF-b signaling inhibitors for cancer therapy, Nat. Rev. Drug Discov. 3 (2004) 1011-1022.
173. J.S. Sawyer, B.D. Anderson, D.W. Beight, T. Goodson, D.K. Herron, H.Y. Li, W.T. McMillen, N. Mort, S. Parsons, E.C.R. Smith, K.S. Britt, L. Yan, F. Zhang, J.M. Yingling, Synthesis and activity of new aryl-and heteroaryl-substituted 5, 6-dihydro-4H-pyrrolo[1, 2-b]pyrazole inhibitors of the transforming growth factor-type I receptor kinase domain, Bioorg. Med. Chem. Lett. 14 (2004) 3581-3585.
174. H. Li, W.T. McMillen, C.R. Heap, D.J. McCann, L. Yan, R.M. Campbell, S.R. Mundla, C.H.R. King, E.A. Dierks, B.D. Anderson, K.S. Britt, K.L. Huss, M.D. Voss, Y. Wang, D.K. Clawson, J.M. Yingling, J.S. Sawyer, Optimization of a dihydropyrrolopyrazole series of transforming growth factor-b type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-b receptor type I inhibitor as antitumor agent, J. Med. Chem. 51 (2008) 2302-2306.
175. J. Matsui, Y. Funahashi, T. Uenaka, T. Watanabe, A. Tsuruoka, M. Asada, Multikinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase, Clin. Cancer Res. 14 (2008) 5459-5465.
176. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm.
177. J.S. Lazo, D.C. Aslan, E.C. Southwick, K.A. Cooley, A.P. Ducruet, B. Joo, A. Vogt, P. Wipf, Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25, J. Med. Chem. 44 (2001) 4042-4049.
178. S. Cory, D.C.S. Huang, J.M. Adams, The Bcl-2 family: roles in cell survival and oncogenesis, Oncogene 22 (2003) 8590-8607.
179. C. Bodur, H. Basaga, Bcl-2 inhibitors: emerging drugs in cancer therapy, Curr. Med. Chem. 19 (2012) 1804-1820.
180. A.S. Azmi, Z. Wang, P.A. Philip, R.M. Mohammad, F.H. Sarkar, Emerging Bcl-2 inhibitors for the treatment of cancer, Expert Opin. Emerg. Drugs 16 (2011) 59-70.
181. N. Bajwa, C. Liao, Z.N. Coleska, Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review, Expert Opin. Ther. Pat. 22 (2012) 37-55.
182. S. Broch, B. Aboab, F. Anizon, P. Moreau, Synthesis and in vitro antiproliferative activities of quinoline derivatives, Eur. J. Med. Chem. 45 (2010) 1657-1662.
183. S. Broch, H. Henon, A.L. Debaud, M.L. Fogeron, N.B. B-erard, F. Anizon, P. Moreau, Synthesis and biological activities of new di-and trimeric quinoline derivatives, Bioorg. Med. Chem. 18 (2010) 7132-7143.
184. E. Saugues, L. Nauton, V. Th-ery, F. Anizon, P. Moreau, Synthesis and molecular modeling study of new trimeric quinoline derivatives, Bioorg. Chem. 39 (2011) 143-150.
185. E. Saugues, A.L. Debaud, F. Anizon, N. Bonnefoy, P. Moreau, Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators, Eur. J. Med. Chem. 57 (2012) 112-125.
186. H. Chen, Z. Yang, C. Ding, L. Chu, Y. Zhang, K. Terry, H. Liu, Q. Shen, J. Zhou, Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy, Eur. J. Med. Chem. 62 (2013) 498-507.
187. I.A. Shaikh, F. Johnson, A.P. Grollman, Structureactivity relationship among simple bicyclic analogs. Rate dependent of DNA degradation on quinine reduction potential, J. Med. Chem. 29 (1986) 1329-1340.
188. H.D. Beall, A.M. Murphy, D. Siegel, R.H.J. Hargreaves, J. Butlerand, D. Ross, Nicotinamide adenine dinudeotide (Phosphate): quinone oxidoreductase (DTdiaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines, Mol. Pharmacol. 48 (1995) 499-504.
189. H.D. Beall, Y. Liu, D. Siegel, E.M. Bolton, N.W. Gilson, D. Ross, Role of NAD(P) H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin, Biochem. Pharmacol. 51 (1996) 645-652.
190. C.K. Ryu, H.J. Jeong, S.K. Lee, H.J. You, K.U. Choi, J.Y. Shim, Y.H. Heo, C.O. Lee, Effects of 6-arylamino-5, 8-quinolinediones and 6-chloro-7-arylamino-5, 8-isoquinolinediones on NAD(P)H:quinone oxidoreductase (NQO1) activity and their cytotoxic potential, Arch. Pharm. Res. 24 (2001) 390-896.
191. T. Fryatt, H.I. Pettersson, W.T. Gardipee, K.C. Bray, S.J. Green, A.M.Z. Slawin, H.D. Beall, C.J. Moody, Novel quinolinequinone antitumor agents: structuremetabolism studies with NAD(P)H:quinone oxidoreductase (NQO1), Bioorg. Med. Chem. 12 (2004) 1667-1687.
192. M. Hassani, W. Cai, D.C. Holley, J.P. Lineswala, B.R. Maharjan, G.R. Ebrahimian, H. Seradj, M.G. Stocksdale, F. Mohammadi, C.C. Marvin, J.M. Gerdes, H.D. Beall, M. Behforouz, Novel lavendamycin analogs as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase-1, J. Med. Chem. 48 (2005) 7733-7749.
193. W. Cai, M. Hassani, R. Karki, E.D. Walter, K.H. Koelsch, H. Seradj, J.P. Lineswala, H. Mirzaei, J.S. York, F. Olang, M. Sedighi, J.S. Lucas, T.J. Eads, A.S. Rose, S. Charkhzarrin, N.G. Hermann, H.D. Beall, M. Behforouz, Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents, Bioorg. Med. Chem. 18 (2010) 1899-1909.
194. C.M. Keyari, A.K. Kearns, N.S. Duncan, E.A. Eickholt, G. Abbott, H.D. Beall, P. Diaz, Synthesis of new quinolinequinone derivatives and preliminary exploration of their cytotoxic properties, J. Med. Chem. 56 (2013) 3806-3819.
195. T. Shimizu, Y. Fujiwara, T. Osawa, T. Sakai, K. Kubo, K. Kubo, T. Nishitoba, K. Kimura, T. Senga, H. Murooka, A. Iwai, K. Fukushima, T. Yoshino, A. Miwa, Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors, Bioorg. Med. Chem. Lett. 14 (2004) 875-879.
196. W.Q. Ding, B. Liu, J.L. Vaught, H. Yamauchi, S.E. Lind, Anticancer activity of the antibiotic clioquinol, Cancer Res. 65 (2005) 3389-3395.
197. T. Du, G. Filiz, A. Caragounis, P.J. Crouch, A.R. White, Clioquinol promotes cancer cell toxicity through tumor necrosis factor alpha release from macrophages, J. Pharmacol. Exp. Ther. 324 (2008) 360-367.
198. X. Mao, X. Li, R. Sprangers, X. Wang, A. Venugopal, T. Wood, Y. Zhang, D.A. Kuntz, E. Coe, S. Trudel, D. Rose, R.A. Batey, L.E. Kay, A.D. Schimmer, Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma, Leukemia 23 (2009) 585-590.
199. S.K. Suthar, V. Jaiswal, S. Lohan, S. Bansal, A. Chaudhary, A. Tiwari, A.T. Alex, A. Joesph, Novel quinolone substituted thiazolidin-4-ones as antiinflammatory, anticancer agents: design, synthesis and biological screening, Eur. J. Med. Chem. 63 (2013) 589-602, http://dx.doi.org/10.1016/j.ejmech.2013.03.011.
200. L. Neckers, Hsp90 inhibitors as novel cancer chemotherapeutic agents, Trends Mol. Med. 8 (2002) S55-S61.
201. R.H.J. Hargreaves, C.L. David, L.J. Whitesell, D.V. LaBarbera, A. Jamil, J.C. Chapuis, E.B. Skibo, Discovery of quinolinediones exhibiting a heat shock response and angiogenesis inhibition, J. Med. Chem. 51 (2008) 2492-2501.
202. T. Ganesh, J. Min, P. Thepchatri, Y. Du, L. Li, I. Lewis, L. Wilson, H. Fu, G. Chiosis, R. Dingledine, D. Liotta, J.P. Snyder, A. Sun, Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): synthesis, biology, and molecular modelling, Bioorg. Med. Chem. 16 (2008) 6903-6910.
203. Q. Zhou, Z.K. Melkoumian, A. Lucktong, M. Moniwa, J.R. Davie, J.S. Strobl, Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1, J. Biol. Chem. 275 (2000) 35256-35263.
204. E.D. Eliseeva, V. Valkov, M. Jung, Characterization of novel inhibitors of histone acetyltransferases, Mol. Cancer Ther. 6 (2007) 2391-2398.
205. A. Mai, D. Rotili, D. Tarantino, A. Nebbioso, S. Castellano, G. Sbardella, M. Tini, L. Altucci, Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases, Bioorg. Med. Chem. Lett. 19 (2009) 1132-1135.
206. P.W. Finn, I. Kalvinsh, E. Loza, V. Andrianov, O. Habarova, D. Lolya, I. Piskunova, Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors, US Patent. 2006/0079528 (2006).
207. D. Moffat, S. Patel, F. Day, A. Belfield, A. Donald, M. Rowlands, J. Wibawa, D. Brotherton, L. Stimson, V. Clark, J. Owen, L. Bawden, G. Box, E. Bone, P. Mortenson, A. Hardcastle, S. Meurs, S. Eccles, F. Raynaud, W. Aherne, Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicycle [3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor, J. Med. Chem. 53 (2010) 8663-8678.
208. R. McMillan, W. Matsui, Molecular pathways: the hedgehog signaling pathway in Cancer, Clin. Cancer Res. 18 (2012) 4883-4888.
209. T. Ohashi, Y. Oguro, T. Tanaka, Z. Shiokawa, S. Shibata, Y. Sato, H. Yamakawa, H. Hattori, Y. Yamamoto, S. Kondo, M. Miyamoto, H. Tojo, A. Baba, S. Sasaki, Discovery of pyrrolo[3, 2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors, Bioorg. Med. Chem. 20 (2012) 5496-5506.
210. A. Hakme, H.K. Wong, F. Dantzer, V. Schreiber, The expanding field of poly(ADP-ribosyl)ation reactions, EMBO Rep. 9 (2008) 1094-1100.
211. M. Narwal, H. Venkannagari, L. Lehtio, Structural basis of selective inhibition of human tankyrases, J. Med. Chem. 55 (2012) 1360-1367.
212. R. Wolin, D. Wang, J. Kelly, A. Afonso, L. James, P. Kirschmeier, A.T. McPhail, Bioorg. Med. Chem. Lett. 6 (1996) 195-200.
213. D.W. End, G. Smets, A.V. Todd, T.L. Applegate, C.J. Fuery, P. Angibaud, M. Venet, G. Sanz, H. Poignet, S. Skrzat, A. Devine, W. Wouters, C. Bowden, Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro, Cancer Res. 61 (2001) 131-137.
214. R. Kurzrock, M. Albitar, J.E. Cortes, Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome, J. Clin. Oncol. 22 (2004) 1287-1292.
215. C.Z. Ding, J.T. Hunt, C. Ricca, V. Manne, 3-Imidazolylmethylaminophenylsulfonyl tetrahydroquinolines, a novel series of farnesyltransferase inhibitors, Bioorg. Med. Chem. Lett. 10 (2000) 273-275.
216. S. Adsule, V. Barve, D. Chen, F. Ahmed, Q.P. Dou, S. Padhye, F.H. Sarkar, Novel schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells, J. Med. Chem. 49 (2006) 7242-7246.
217. J. Vukanovic, A. Passaniti, T. Hirata, R.J. Traystman, B.H. Asp, J.T. Isaacs, Antiangiogenic effects of the quinoline-3-carboxamide linomide, Cancer Res. 53 (1993) 1833-1837.
218. T.L. Su, T.C. Chou, J.Y. Kim, J.T. Huang, G. Ciszewska, W.Y. Ren, G.M. Otter, F.M. Sirotnak, K.A. Watanabe, J. Med. Chem. 38 (1995) 3226-3235.
219. T. Suzuki, N. Fukazawa, K. Sannohe, W. Sato, O. Yano, T. Tsuruo, Structureactivity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer, J. Med. Chem. 40 (1997) 2047-2052.
220. P. Shrivastava, M. Hanibuchi, S. Yano, P. Parajuli, T. Tsuruo, S. Sone, Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil, Cancer Chemother. Pharmacol. 42 (1998) 483-490.
221. A. Ito, L.A. Shamon, B. Yu, E.M. Greenwood, S.K. Lee, R.B. vanBreemen, R.G. Mehta, N.R. Farnsworth, H.H.S. Fong, J.M. Pezzuto, A.D. Kinghorn, Antimutagenic constituents of Casimiroa edulis with potential Cancer chemopreventive activity, J. Agric. Food Chem. 46 (1998) 3509-3516.
222. Z.Y. Yang, Y. Xia, P. Xia, Y. Tachibana, K.F. Bastow, K.H. Lee, Synthesis and cytotoxicity of substituted 8, 8-dimethyl-2H, 8H-pyrano[6, 5-h]quinoline-2-one and related compounds, Bioorg. Med. Chem. Lett. 9 (1999) 713-716.
223. M.G. Ferlin, B. Gatto, G. Chiarelotto, M. Palumbo, Pyrrolo-quinoline derivatives as potential antineoplastic drugs, Bioorg. Med. Chem. 8 (2000) 1415-1422.
224. K.C. Fang, Y.L. Chen, J.Y. Sheu, T.C. Wang, C.C. Tzeng, Synthesis, antibacterial, and cytotoxic evaluation of certain 7-substituted norfloxacin derivatives, J. Med. Chem. 43 (2000) 3809-3812.
225. M.E. Suh, M.J. Kang, H.W. Yoo, S.Y. Park, C.O. Lee, Synthesis and cytotoxicity of 2-methyl-1-substituted-imidazo[4, 5-g]quinoline-4, 9-dione and 7, 8-dihydro-10H-[1, 4]oxazino [30, 40:2, 3]imidazo[4, 5-g]quinoline-5, 12-dione derivatives, Bioorg. Med. Chem. 8 (2000) 2079-2083.
226. J. Chen, L.W. Deady, J.A. Desneves, A.J. Kaye, G.J. Finlay, B.C. Baguley, W.A. Denny, Synthesis of substituted indeno[1, 2-b]quinoline-6-carboxamides, [1]benzothieno[3, 2-b]quinoline-4-carboxamides and 10Hquindoline-4-carboxamides: evaluation of structure activity relationships for cytotoxicity, Bioorg. Med. Chem. 8 (2000) 2461-2466.
227. T. Tsuchiya, Y. Takagi, H. Yamada, Preparation of 5-(2, 6-dideoxy-2-fluoro-al-talopyranosyloxy)-6-hydroxynaphtho [2, 3-f]quinoline-7, 12-dione (FT-Alz), a new-type, potentially antitumor substance with various biological activities, Bioorg. Med. Chem. Lett. 10 (2000) 203-207.
228. C. Lamazzi, S. Leonce, B. Pfeiffer, P. Renard, G. Guillaumet, C.W. Rees, T. Besson, Expeditious synthesis and cytotoxic activity of new cyanoindolo [3, 2-c]quinolines and benzimidazo[1, 2-c]quinazolines, Bioorg. Med. Chem. Lett. 10 (2000) 2183-2185.
229. H. Lee, J. Lee, S.S. Hong, S. Yang, S.H. lung, Y. Jahng, J. Cho, Synthesis and in vitro cytotoxicity of 2-alkylaminosubstituted quinoline derivatives, Arch. Pharm. Res. 23 (2000) 450-454.
230. H. Lee, J. Lee, S. Yang, Synthesis and in vitro cytotoxicity of 4-alkyl-or 4-aryl aminosubstituted cyclopenta [c]quinoline derivatives, Arch. Pharm. Res. 24 (2001) 385-389.
231. L.W. Deady, J. Desneves, A.J. Kaye, G.J. Finlay, B.C. Baguley, W.A. Denny, Positioning of the carboxamide side chain in 11-oxo-11H-indeno [l, 2-b] quinoline carboxamide anticancer agents: effects on cytotoxicity, Bioorg. Med. Chem. 9 (2001) 445-452.
232. S. Hazeldine, L. Polin, J. Kushner, K. White, N.H. Bouregeois, B. Crantz, E. Palomino, T.H. Corbett, J.P. Horwitz, Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), J. Med. Chem. 45 (2002) 3130-3137.
233. H. Lee, I. Jeong, S. Yang, Design and synthesis of isoindoloquinoline derivatives as potential antitumor agents, Arch. Pharm. Res. 25 (2002) 416-420.
234. L.W. Deady, T. Rodemann, L. Zhuang, B.C. Baguley, W.A. Denny, Synthesis and cytotoxic activity of carboxamide derivatives of benzo [b] [1, 6]naphthyridines, J. Med. Chem. 46 (2003) 1049-1054.
235. L. He, H.X. Chang, T.C. Chou, N. Savaraj, C.C. Cheng, Design of antineoplastic agents based on the '2-phenylnaphthalenetype' structural pattern-synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives, Eur. J. Med. Chem. 38 (2003) 101-107.
236. J.R. Patel, A.V. Dobaria, B.P. Kansagra, A.R. Parikh, Synthesis of cyanopyridines and cyanopyrans bearing 2-chloro-6-bromoquinoline nucleus as potential antimicrobial and anticancer agents, Indian J. Heterocycl. Chem. 12 (2003) 237-240.
237. M.T. Vazquez, M. Romero, M.D. Pujol, Synthesis of novel 2, 3-dihydro-1, 4-dioxino [2, 3-g]quinoline derivatives as potential antitumor agents, Bioorg. Med. Chem. 12 (2004) 949-956.
238. E. Delfourne, R. Kiss, L.L. Corre, F. Dujols, J. Bastide, F. Collignon, B. Lesur, A. Frydman, F. Darro, Synthesis and in vitro antitumor activity of ring C and D-substituted phenanthrolin-7-one derivatives, analogs of the marine pyridoacridine alkaloids ascididemin and meridine, Bioorg. Med. Chem. 12 (2004) 3987-3994.
239. Y.L. Chen, H.M. Hung, C.M. Lu, K.C. Li, C.C. Tzeng, Synthesis and anticancer evaluation of certain indolo [2, 3-b]quinoline derivatives, Bioorg. Med. Chem. 12 (2004) 6539-6546.
240. Y.L. Chen, I.L. Chen, T.C. Wang, C.H. Han, C.C. Tzeng, Synthesis and anticancer evaluation of certain 4-anilinofuro [2, 3-b]quinoline and 4-anilinofuro[3, 2-c] quinoline derivatives, Eur. J. Med. Chem. 40 (2005) 928-934.
241. M.G. Ferlin, C. Marzano, L.D. Via, A. Chilin, G. Zagotto, A. Guiotto, S. Moro, New water soluble pyrroloquinoline derivatives as new potential anticancer agents, Bioorg. Med. Chem. 13 (2005) 4733-4739.
242. Y.L. Zhao, Y.L. Chen, F.S. Chang, C.C. Tzeng, Synthesis and cytotoxic evaluation of certain 4-anilino-2-phenylquinoline derivatives, Eur. J. Med. Chem. 40 (2005) 792-797.
243. S.R. Amini, A. Khalaj, A. Shafiee, M. Daneshtalab, Antitumor activity of new quinoline derivatives in human breast cancer T47D cells, Int. J. Cancer Res. 2 (2006) 102-108.
244. M. Dzieduszycka, M.M.B. Gracz, B. Stefanska, S. Martelli, A. Piwkowska, M. Arciemiuk, E. Borowski, Synthesis of 7-oxo-7H-naphtho[1, 2, 3-de]quinoline derivatives as potential anticancer agents active on multidrug resistant cell lines, Bioorg. Med. Chem. 14 (2006) 2880-2886.
245. Y.L. Chen, Y.L. Zhao, C.M. Lu, C.C. Tzeng, J.P. Wang, Synthesis, cytotoxicity, and anti-inflammatory evaluation of 2-(furan-2-yl)-4-(phenoxy)quinoline derivatives, Bioorg. Med. Chem. 14 (2006) 4373-4378.
246. M. Behforouz, W. Cai, F. Mohammadi, M.G. Stocksdale, Z. Gu, M. Ahmadian, D.E. Baty, M.R. Etling, C.H. Al-Anzi, T.M. Swiftney, L.R. Tanzer, R.L. Merriman, N.C. Behforouz, Synthesis and evaluation of antitumor activity of novel Nacyllavendamycin analogs and quinoline-5, 8-diones, Bioorg. Med. Chem. 15 (2007) 495-510.
247. E. Paliakov, M. Henary, M. Say, S.E. Patterson, A. Parker, L. Manzel, D.E. Macfarlane, A.J. Bojarskid, L. Strekowskia, Fujita-Ban QSAR analysis and CoMFA study of quinoline antagonists of immunostimulatory CpG-oligodeoxynucleotides, Bioorg. Med. Chem. 15 (2007) 324-332.
248. G. Gakhar, A. Shi, D.H. Hua, T.A. Nguyen, Antitumor effect of substituted quinolines in breast cancer cells, Drug Dev. Res. 69 (2008) 526-534.
249. A. Shi, T.A. Nguyen, S.K. Battina, S. Rana, D.J. Takemoto, P.K. Chiangd, D.H. Huaa, Synthesis and anti-breast cancer activities of substituted quinolines, Bioorg. Med. Chem. Lett. 18 (2008) 3364-3368.
250. M.E. Katsarou, E.K. Efthimiadou, G. Psomas, A. Karaliota, D. Vourloumis, Novel copper(II) complex of N-propyl-norfloxacin and 1, 10-phenanthroline with enhanced antileukemic and DNA nuclease activities, J. Med. Chem. 51 (2008) 470-478.
251. S.I. Alqasoumi, A.M. Al-Taweel, A.M. Alafeefy, M.M. Hamed, E. Noaman, M.M. Ghorab, Synthesis and biological evaluation of 2-amino-7, 7-dimethyl-4-substituted-5-oxo-1-(3, 4, 5-trimethoxy)-1, 4, 5, 6, 7, 8-hexahydro-quinoline-3-carbonitrile derivatives as potential cytotoxic agents, Bioorg. Med. Chem. Lett. 19 (2009) 6939-6942.
252. S.C.C. Martins, The Anticancer Potential of CITme, a Quinoline Derivative (M.Sc. dissertation), University of Pretoria, Pretoria, 2010, http://upetd.up.ac. za/thesis/available/etd-07082011-155804/.
253. S.A. Al-Trawneh, J.A. Zahra, M.R. Kamal, M.M. El-Abadelah, F. Zani, M. Incerti, A. Cavazzoni, R.R. Alfieri, P.G. Petronini, P. Vicini, Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents, Bioorg. Med. Chem. 18 (2010) 5873-5884.
254. B.S. Creaven, B. Duff, D.A. Egan, K. Kavanagh, G. Rosair, V.R. Thangella, M.Walsh, Anticancer and antifungal activity of copper(II) complexes of quinolin-2(1H)-one-derived Schiff bases, Inorg. Chim. Acta 363 (2010) 4048-4058.
255. H.A.S. Abbas, H.N. Hafez, A.R.B.A. El-Gazzar, Synthesis, in vitro antimicrobial and in vivo antitumor evaluation of novel pyrimidoquinolines and its nucleoside derivatives, Eur. J. Med. Chem. 46 (2011) 21-30.
256. R.V. Patel, P. Kumari, D.P. Rajani, K.H. Chikhalia, Synthesis and studies of novel 2-(4-cyano-3-trifluoromethylphenyl amino)-4-(quinoline-4-yloxy)-6-(piperazinyl/piperidinyl)-s-triazines as potential antimicrobial, antimycobacterial and anticancer agents, Eur. J. Med. Chem. 46 (2011) 4354-4365.
257. X.J. Wang, D.L. Gong, J.D. Wangb, J. Zhang, C.X. Liu, W.S. Xiang, A new quinoline derivative with cytotoxic activity from Streptomyces sp. neau50, Bioorg. Med. Chem. Lett. 21 (2011) 2313-2315.
258. S. Boryczka, W. Mol, M. Milczarek, J. Wietrzyk, E. Bebenek, Synthesis and in vitro antiproliferative activity of novel (4-chloro-and 4-acyloxy-2-butynyl)thioquinolines, Med. Chem. Res. 20 (2011) 1402-1410.
259. K. Sidoryk, M. S witalska, J. Wietrzyk, A. Jaromin, M. Pie tka-Ottlik, P. Cmoch, J. Zagrodzka, W. Szczepek,. Kaczmarek, W.P. Czoch, Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents, J. Med. Chem. 55 (2012) 5077-5087.
260. R.C. Montenegro, L.V. Lotufo, M.O. de Moraes, C. Pessoa, F.A.R. Rodrigues, M.L.F. Bispo, C.C. deAlcantara, C.R. Kaiser, M.V.N. deSouza, 1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer, Med. Chem. Res. 21 (2012) 3615-3619.
261. V.V. Kouznetsov, F.A.R. Ruíz, L.Y.V. Mendez, M.P. Gupta, Simple C-2-substituted quinolines and their anticancer activity, Lett. Drug Des. Dis. 9 (2012) 680-686.
262. Y. Ai, Y.J. Liang, J.C. Liu, H.W. He, Y. Chen, C. Tang, G.Z. Yang, L.W. Fu, Synthesis and in vitro antiproliferative evaluation of pyrimido[5, 4-c]quinoline-4-(3H)-one derivatives, Eur. J. Med. Chem. 47 (2012) 206-213.
263. R. Abonia, D. Insuasty, J. Castillo, B. Insuasty, J. Quiroga, M. Nogueras, J. Cobo, Synthesis of novel quinoline-2-one based chalcones of potential anti-tumor activity, Eur. J. Med. Chem. 57 (2012) 29-40.
264. L. Wang, M. Switalska, Z.W. Mei, W.J. Lu, Y. Takahara, X.W. Feng, I.E. El-Sayed, J. Wietrzyk, T. Inokuchi, Synthesis and in vitro antiproliferative activity of new 11-aminoalkylamino-substituted 5H-and 6H-indolo[2, 3-b]quinolines; structureeactivity relationships of neocryptolepines and 6-methyl congeners, Bioorg. Med. Chem. 20 (2012) 4820-4829.
265. A.R. Ellanki, A. Islam, V.S. Rama, R.P. Pulipati, D. Rambabu, G.R. Krishna, C.M. Reddy, K. Mukkanti, G.R. Vanaja, A.M. Kalle, K.S. Kumar, M. Pal, Solvent effect on copper-catalyzed azide-alkyne cycloaddition (CuAAC): synthesis of novel triazolyl substituted quinolines as potential anticancer agents, Bioorg. Med. Chem. Lett. 22 (2012) 3455-3459.
266. M.M. Ghorab, F.A. Ragab, H.I. Heiba, Y.M. Nissan, W.M. Ghorab, Novel brominated quinoline and pyrimidoquinoline derivatives as potential cytotoxic agents with synergistic effects of g-radiation, Arch. Pharm. Res. 35 (2012) 1335-1346.
267. H. Sarkarzadeh, R. Miri, O. Firuzi, M. Amini, N. Razzaghi-Asl, N. Edraki, A. Shafiee, Synthesis and antiproliferative activity evaluation of imidazolebased indeno[1, 2-b]quinoline-9, 11-dione derivatives, Arch. Pharm. Res. 36 (2013) 436-447.
268. P.S. Rao, C. Kurumurthy, B. Veeraswamy, G.S. Kumar, P.S. Rao, R. Pamanji, J.V. Rao, B. Narsaiah, Synthesis of novel 2-alkyl triazole-3-alkyl substituted quinoline derivatives and their cytotoxic activity, Bioorg. Med. Chem. Lett. 23 (2013) 1225-1227.
269. R.K. Arafa, G.H. Hegazy, G.A. Piazza, A.H. Abadi, Synthesis and in vitro antiproliferative effect of novel quinoline based potential anticancer agents, Eur. J. Med. Chem. 63 (2013) 826-832.
270. N. Kumar, I. Dhamija, P.V. Raj, B.S. Jayashree, V. Parihar, S.N. Manjula, S. Thomas, N.G. Kutty, C.M. Rao, Preliminary investigation of cytotoxic potential of 2-quinolone derivatives using in vitro and in vivo (solid tumor and liquid tumor) models of cancer, Arab. J. Chem. (2012). http://dx.doi.org/10. 1016/j.arabjc.2012.12.029.
271. N.S. El-Gohary, Synthesis and in vitro antitumor activity of new quinoline, pyrimido[4, 5-b]quinoline, [1, 2, 3]triazino[4, 5-b]quinoline, and [1, 2, 4]triazolo[20, 30:3, 4] pyrimido[6, 5-b]quinoline analogs, Med. Chem. Res. 22 (2013) 5236-5247.
272. A.M. El-Agrody, H.S.M. Abd-Rabboh, A.M. Al-Ghamdi, Synthesis, antitumor activity, and structureeactivity relationship of some 4H-pyrano[3, 2-h] quinoline and 7H-pyrimido[40, 50:6, 5]pyrano[3, 2-h]quinoline derivatives, Med. Chem. Res. 22 (2013) 1339-1355.
273. A.M. El-Agrody, E.S.A.E.H. Khattab, A.M. Fouda, A.M. Al-Ghamdi, Synthesis and antitumor activities of certain novel 2-amino-9-(4-halostyryl)-4H-pyrano[3, 2-h]quinoline derivatives, Med. Chem. Res. 21 (2012) 4200-4213.
274. W.J. Lu, M. Switalska, L. Wang, M. Yonezawa, I.E. El-Sayed, J. Wietrzyk, T. Inokuchi, In vitro antiproliferative activity of 11-aminoalkylaminosubstituted 5H-indolo [2, 3-b]quinolines; improving activity of neocryptolepines by installation of ester substituent, Med. Chem. Res. 22 (2013) 4492-4504.
275. Chih-Hua Tseng, Chun-Kuang Lin, Yeh-Long Chen, Chih-Yao Hsu, Huey-Nan Wu, Chin-Kai Tseng, Jin-Ching Lee, Synthesis, antiproliferative and antidengue virus evaluations of 2-aroyl-3-arylquinoline derivatives, Eur. J. Med. Chem. 79 (2014) 66-76.